Drug Trial Radar · NCT04554953
A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia
Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,877
Actual
Start
Apr 13, 2020
Primary completion
Nov 3, 2021
Study completion May 31, 2022
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effectiveness of a combination drug containing fimasartan and statins on the control of hypertension and dyslipidemia, and the secondary objective is to evaluate the drug cost reduction effect, patients' satisfaction level and safety of the combination drug administration.
Conditions
- Hypertension and Dyslipidemia
Interventions
Combination drug containing fimasartan and statinsDrug
Patients who correspond to one of the following: 1. Patients who are planning to be treated with a combination drug containing fimasartan and statins after being newly diagnosed with essential hypertension and primary hypercholesterolemia 2. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension or primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB or dyslipidemia treatment that is containing a statin 3. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension and primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB and dyslipidemia treatment that is containing a statin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood pressure controlled to the target levelTime frame: Week12
- LDL-C controlled to the target levelTime frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chonnam National University Hospital
Gwangju, Jebong-ro, Jangseong-eup, Jangseong-gun, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.